Chemotherapeutic advances in pancreatic cancer

被引:24
作者
Jordan D. Berlin
Mace L. Rothenberg
机构
[1] Vanderbilt University,Division of Oncology, Vanderbilt Ingram Cancer Center
关键词
Pancreatic Cancer; Docetaxel; Gemcitabine; Clin Oncol; Oxaliplatin;
D O I
10.1007/s11912-003-0113-8
中图分类号
学科分类号
摘要
Advances in chemotherapy for pancreatic cancer have been limited. In the past decade, the standard therapy for metastatic disease has switched from 5-fluorouracil (5-FU) to gemcitabine. However, several other cytotoxic agents have shown limited but promising efficacy in pancreatic cancer, and many of these appear to be well suited for combination chemotherapy. Although 5-FU and cisplatin have not demonstrated substantial survival benefits when combined with gemcitabine, results of several phase III trials with other agents are still pending. For locally advanced disease, most recent studies have incorporated gemcitabine into combined-modality therapy. Similarly, in surgically resectable disease, current trials are incorporating gemcitabine into adjuvant therapy. Other trials are using neoadjuvant therapy as a possible means to improve upon current surgical results. However, much hope comes from the development of newer “targeted” therapies for this disease. Although matrix metalloproteinase inhibitors and farnesyl transferase inhibitors did not appear to be effective in initial studies, other targeted therapies are beginning to enter clinical trials.
引用
收藏
页码:219 / 226
页数:7
相关论文
共 177 条
[1]  
Burris HA(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[2]  
Moore MJ(1999)Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma [abstract] Proc ASCO 18 273a-273a
[3]  
Andersen J(2002)Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU)with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 3130-3136
[4]  
Tempero M(2002)A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma Ann Oncol 13 1185-1191
[5]  
Plunkett W(2002)Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 160-164
[6]  
Ruiz van Haperen V(2002)A phase II and pharmacokinetic trial of S-1 in paitents with advanced pancreatic cancer (APC) [abstract] Proc ASCO 21 682a-682a
[7]  
Maisey N(2000)Phase II study of the multitargeted antifolate LY 231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer Ann Oncol 11 101-103
[8]  
Chau I(2002)A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer [abstract] Proc ASCO 21 144a-144a
[9]  
Cunningham D(1999)A phase II trial of Caelyx (liposomal doxorubicin, Doxil) in the treatment of advanced pancreatic carcinoma [abstract] Proc ASCO 18 306a-306a
[10]  
Ducreux M(1985)Phase II study of epirubicin in advanced adenocarcinoma of the pancreas Eur J Cancer Clin Oncol 21 191-194